Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
Doctors are studying a new treatment for a type of cancer called multiple myeloma. They want to see if combining four drugs, selinexor, carfilzomib, daratumumab, and dexamethasone, can help patients who have not gotten better with other treatments. Selinexor may stop cancer cells from growing by blocking a protein called CRM1. Carfilzomib helps cells identify and destroy damaged proteins, and daratumumab may stop cancer cells from growing and spreading. Dexamethasone is an anti-inflammatory drug that helps the other drugs work better. The doctors think that using these four drugs together may work better than just using some of them.
Doctors are studying a new treatment for a type of cancer called multiple myeloma. They want to see if combining four drugs, selinexor, carfilzomib, daratumumab, and dexamethasone, can help patients who have not gotten better with other treatments. Selinexor may stop cancer cells from growing by blocking a protein called CRM1. Carfilzomib helps cells identify and destroy damaged proteins, and daratumumab may stop cancer cells from growing and spreading. Dexamethasone is an anti-inflammatory drug that helps the other drugs work better. The doctors think that using these four drugs together may work better than just using some of them.
*Third Opinion AI Generated Synopsis
Trial Summary
This phase II trial studies the effect of selinexor when combined with carfilzomib, daratumumab, and dexamethasone in treating patients with high-risk multiple myeloma that has come back (recurrent) or has not responded to treatment (refractory) and who have received 1-3 prior lines of therapy. Selinexor may stop the growth of cancer cells by blocking a protein called CRM1 that is needed for cell growth. Carfilzomib is a type of drug called a proteasome inhibitor. A proteasome is a protein found within cells that has the important role of identifying and marking damaged proteins that are needed to be destroyed by the cell for survival. The inhibition of the proteasome allows for damaged protein to accumulate within cells. This accumulation of damaged protein causes the cell to die. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving selinexor in combination with carfilzomib, daratumumab, and dexamethasone may work better than carfilzomib, daratumumab, and dexamethasone alone in treating patients with multiple myeloma.
This phase II trial studies the effect of selinexor when combined with carfilzomib, daratumumab, and dexamethasone in treating patients with high-risk multiple myeloma that has come back (recurrent) or has not responded to treatment (refractory) and who have received 1-3 prior lines of therapy. Selinexor may stop the growth of cancer cells by blocking a protein called CRM1 that is needed for cell growth. Carfilzomib is a type of drug called a proteasome inhibitor. A proteasome is a protein found within cells that has the important role of identifying and marking damaged proteins that are needed to be destroyed by the cell for survival. The inhibition of the proteasome allows for damaged protein to accumulate within cells. This accumulation of damaged protein causes the cell to die. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving selinexor in combination with carfilzomib, daratumumab, and dexamethasone may work better than carfilzomib, daratumumab, and dexamethasone alone in treating patients with multiple myeloma.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: